5JUR

PB2 bound to an azaindole inhibitor


Experimental Data Snapshot

  • Method: X-RAY DIFFRACTION
  • Resolution: 2.93 Å
  • R-Value Free: 0.198 
  • R-Value Work: 0.181 
  • R-Value Observed: 0.181 

wwPDB Validation   3D Report Full Report


Ligand Structure Quality Assessment 


This is version 1.2 of the entry. See complete history


Literature

Discovery of Novel, Orally Bioavailable beta-Amino Acid Azaindole Inhibitors of Influenza PB2.

Farmer, L.J.Clark, M.P.Boyd, M.J.Perola, E.Jones, S.M.Tsai, A.Jacobs, M.D.Bandarage, U.K.Ledeboer, M.W.Wang, T.Deng, H.Ledford, B.Gu, W.Duffy, J.P.Bethiel, R.S.Shannon, D.Byrn, R.A.Leeman, J.R.Rijnbrand, R.Bennett, H.B.O'Brien, C.Memmott, C.Nti-Addae, K.Bennani, Y.L.Charifson, P.S.

(2017) ACS Med Chem Lett 8: 256-260

  • DOI: https://doi.org/10.1021/acsmedchemlett.6b00486
  • Primary Citation of Related Structures:  
    5JUN, 5JUR

  • PubMed Abstract: 

    In our efforts to develop novel small-molecule inhibitors for the treatment of influenza, we utilized molecular modeling and the X-ray crystal structure of the PB2 subunit of the influenza polymerase to optimize a series of acyclic β-amino acid inhibitors, highlighted by compound 4 . Compound 4 showed good oral exposure in both rat and mouse. More importantly, it showed strong potency versus multiple influenza-A strains, including pandemic 2009 H1N1 and avian H5N1 strains and showed a strong efficacy profile in a mouse influenza model even when treatment was initiated 48 h after infection. Compound 4 offers good oral bioavailability with great potential for the treatment of both pandemic and seasonal influenza.


  • Organizational Affiliation

    Vertex Pharmaceuticals Inc. , 50 Northern Avenue, Boston, Massachusetts 02210, United States.


Macromolecules
Find similar proteins by:  (by identity cutoff)  |  3D Structure
Entity ID: 1
MoleculeChains Sequence LengthOrganismDetailsImage
Polymerase basic protein 2169Influenza A virus (A/Beijing/39/1975(H3N2))Mutation(s): 1 
Gene Names: PB2
UniProt
Find proteins for Q30NP1 (Influenza A virus (strain A/Beijing/39/1975 H3N2))
Explore Q30NP1 
Go to UniProtKB:  Q30NP1
Entity Groups  
Sequence Clusters30% Identity50% Identity70% Identity90% Identity95% Identity100% Identity
UniProt GroupQ30NP1
Sequence Annotations
Expand
  • Reference Sequence
Small Molecules
Ligands 1 Unique
IDChains Name / Formula / InChI Key2D Diagram3D Interactions
6NS
Query on 6NS

Download Ideal Coordinates CCD File 
B [auth A](3~{R})-3-[[5-fluoranyl-2-(5-fluoranyl-1~{H}-pyrrolo[2,3-b]pyridin-3-yl)pyrimidin-4-yl]amino]-4,4-dimethyl-pentanoic acid
C18 H19 F2 N5 O2
KLWQRKNCYXQRGD-CYBMUJFWSA-N
Experimental Data & Validation

Experimental Data

  • Method: X-RAY DIFFRACTION
  • Resolution: 2.93 Å
  • R-Value Free: 0.198 
  • R-Value Work: 0.181 
  • R-Value Observed: 0.181 
  • Space Group: P 65
Unit Cell:
Length ( Å )Angle ( ˚ )
a = 81.18α = 90
b = 81.18β = 90
c = 54.43γ = 120
Software Package:
Software NamePurpose
SCALAdata scaling
BUSTER-TNTrefinement
PDB_EXTRACTdata extraction
BUSTERphasing
XDSdata scaling

Structure Validation

View Full Validation Report



Ligand Structure Quality Assessment 


Entry History 

Deposition Data

  • Released Date: 2017-03-01 
  • Deposition Author(s): Jacobs, M.D.

Revision History  (Full details and data files)

  • Version 1.0: 2017-03-01
    Type: Initial release
  • Version 1.1: 2017-11-22
    Changes: Refinement description
  • Version 1.2: 2023-09-27
    Changes: Data collection, Database references, Refinement description